Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pentetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.46 |
| ▸ | CA4 known ✓ | P22748 | 7/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.37 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL6669360 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL342065 | 0.97 | KDM4E (0.81) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL6669353 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL449956 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL30903920 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL30690408 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL29363230 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL276109 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL570988 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL30259751 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0367787-B2 | METHOD FOR ENHANCING THE SAFETY OF METAL-LIGAND CHELATES AS X-RAY CONTRAST AGENTS | MALLINCKRODT INC (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5204085-A | Adding calcium salts | MALLINCKRODT MEDICAL, INC. (US) | 1993-04-20 | — | — | US | disclosed |